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Abstract
Objective: to review the most recent data on the impact of the primary treatment and 
individual factors on ovarian cancer patient survival and to study it in a real world 
population. Methods/materials: retrospective analysis of 147 consecutive ovarian cancer 
patients treated with platin-based chemotherapy, either after primary debulking sur-
gery (PDS) (n = 94, 64%) or as neoadjuvant (NACT) treatment (53, 36%). Results: NACT 
patients were older (64.3 vs. 58.2 years), with radiologically unresectable disease (74%) 
and/or comorbidities (26%). Fifty-five percent of pts. submitted to PDS were staged III/
IV. Serous carcinomas were equally distributed (PDS-57% vs. NACT-60%) but endome-
trioid (20 vs. 4%) and carcinomas not otherwise specified (6 vs. 30%) were more fre-
quently diagnosed in the PDS and NACT group, respectively. Genetic diagnosis (24.4%): 
11 BRCA1/2 and 1 RAD51C carriers identified. Residual disease after surgery was the 
only significant prognostic factor for both relapse (HR = 2267) and death (HR = 1847). 
Primary debulking surgery was associated with a significantly better PFS (HR = 0.541; 
p = 0.012) and with a trend to a better OS (HR = 0.714; p = 0.296). For pts. with III/IV dis-
ease OS was significantly superior in the PDS group. Conclusion: residual disease was 
the only significant prognostic factor. Primary surgery was associated with a significantly 
better PFS. The difference in OS was significant in stage III/IV patients. This reinforces the 
importance of maximal cytoreduction.
Keywords: epithelial ovarian cancer, neoadjuvant therapy, primary surgery
1. Introduction
Ovarian cancer (OC) is the most lethal gynaecological malignancy in developed coun-
tries, with over 225.000 new cases and more than 140.000 deaths every year worldwide [1]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Epithelial OC is currently divided into seven main subtypes: serous, endometrioid, clear 
cell, mucinous, transitional cell, mixed and undifferentiated and unclassified OC [2]. Due to 
inadequate screening and a lack of early clinical symptoms, 70% of women with OC present 
with advanced disease, associated with high morbidity and mortality [1, 3]. The standard of 
care for OC treatment comprises maximal cytoreductive resection aiming to remove all vis-
ible tumour tissue, followed by platinum-taxane chemotherapy [4]. However, most patients 
relapse within the first 5 years after diagnosis, with a median progression-free survival (PFS) 
of 11 to 18 months and a median overall survival (OS) of 24 to 38 months [5, 6]. Data from 
the EUROCARE show a 5-year age-standardised relative survival of 37.6% [7]. Data from the 
National Cancer Institute show a 5-year survival of 46.2% [8].
Many OC patient characteristics are associated with survival, like stage [9, 10], histology 
[10–14], residual disease and debulking status after cytoreductive surgery [10, 12, 14, 15], type 
of chemotherapy [6, 10, 13, 16] and BRCA status [17, 18]. Maximal surgery, even when total 
absence of residual disease cannot be obtained, seems to relate to survival advantage [19]. The 
expertise of the surgical team is important in providing optimal cytoreduction without com-
promising post-operative morbidity [20].
A subgroup of OC patients is found to have surgically unresectable cancer and prediction 
criteria for suboptimal cytoreduction are important in treatment decisions. Studies using 
computed tomography (CT) suggested that the presence of an omental cake extending to 
the spleen, a diaphragm coated by tumour or lesions >2 cm in the suprarenal, para-aortic 
lymph-nodes and porta hepatis, among others [21], were predictors of unresectable disease. 
Other features predicting the outcome of cytoreduction correspond to traditionally difficult 
anatomic locations, such as extensive upper abdominal disease [22]. Recently, the Society of 
Gynecologic Oncology and the American Society of Clinical Oncology published the latest 
guidelines on neoadjuvant chemotherapy (NACT), stating the predictors of suboptimal cyto-
reduction. These include radiological predictors, such as retroperitoneal lymph-nodes above 
the renal hilum >1 cm, diffuse small bowel adhesions or thickening, small bowel mesentery 
lesions >1 cm, root of the superior mesenteric artery lesions >1 cm, perisplenic lesions >1 cm, 
lesser sac lesions >1 cm, and ascites on at least two-thirds of CT scan slices; and clinical predic-
tors such as age ≥ 60 years and CA-125 ≥ 500 U/mL [23].
Interval debulking surgery (IDS) after NACT for patients with unresectable disease criteria is 
still controversial. A meta-analysis [24] suggested that NACT was associated with a worse out-
come, but in 2010 a study concluded that it was not inferior to primary debulking surgery (PDS) 
in bulky stage IIIC or IV OC [25]. Moreover, it was associated to significantly lower adverse 
effects, such as postoperative infections, venous complications, fistula and haemorrhage, as 
well as lower postoperative mortality rates [25–27]. Other studies, such as the SCORPION 
and the JCOG0602 trials, seem to confirm these findings [23]. Some phase III trials suggested 
that NACT would also lead to improved quality of life [28–30]. Preoperative predictors for 
complete cytoreduction and outcomes from NACT are needed and subject of research [31].
The decision of treating advanced OC patients with NACT became more frequent [32], but 
there are still unsolved issues. Staging is surgical and based on laparotomy findings. Residual 
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disease after surgery is a major prognostic factor for survival [14, 25] and visual evaluation 
by the surgeon is critical to conclude about intra-abdominal tumour spread. Whether the 
surgeons’ statement of complete tumour resection is equal in primary surgery and in IDS 
remains unclear. Microscopically carcinomatous areas may have a benign visual appearance 
after NACT [33] interfering with the visual evaluation of tumour extension and potentially 
leading to incomplete cytoreduction. Also, the possibility that NACT may induce platinum 
resistance [34, 35] remains unclear. A recent study revealed that although the proportion of 
platinum-resistant recurrence after NACT and IDS was superior, this difference was not sig-
nificant. A significant difference was only observed when women who had a recurrence were 
retreated with platinum-based chemotherapy [36].
The highest risk associated with NACT may be that patients with significant side effects 
and refractory disease will lose the opportunity for debulking surgery [37], although it 
has been suggested that these patients have a poor prognosis and should be encouraged 
to participate in clinical trials or to discontinue active cancer therapy [23]. Another limita-
tion of NACT is the insufficient data supporting the use of intraperitoneal (IP)/intravenous 
(IV) chemotherapy as adjuvant treatment after NACT [23]. Recent results from the OV21/
PETROC trial seem to support that a carboplatin-based IP regimen, after NACT and deb-
ulking surgery, is well tolerated and associated with a higher PFS compared to IV therapy 
(immature data) [38].
Besides patient characteristics, survival depends on treatment decisions and questions remain 
about the reproducibility of study data in routine clinical practice. We tried to review the most 
recent data on the primary treatment of OC and the factors that have impact on the survival of 
these patients. Therefore, our objective was to characterise a consecutive series of OC patients 
treated in our centre and to analyse the effect of patient variables and decision criteria on effi-
cacy outcomes for patients treated with either PDS or primary NACT.
2. Material and methods
This study is a retrospective analysis. It includes all patients with epithelial OC observed 
in the Gynaecological Oncology multidisciplinary group of our centre and registered in the 
South Portuguese Cancer Registry (ROR-Sul), between January 2006 and December 2011. 
Medical records were reviewed, and demographic, clinical, surgical, pathologic, molecular 
and follow-up information obtained. Optimal cytoreduction was defined as no macroscopic 
residual disease at the end of surgery. Pathology data were collected from the pathology 
report after citoreductive surgery. The chemotherapy regimen used was the doublet of carbo-
platin (AUC = 6) and paclitaxel (175 mg/m2 of body surface). Progression data were obtained 
from clinical notes: most were confirmed by CT scan and CA125 measurement criteria. In less 
than 5% of cases, progression was assumed by CA125 measurement and clinical examina-
tion. Information concerning molecular testing was obtained from patients previously coun-
selled and given informed consent through procedures and forms approved by the Ethics 
Committee.
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2.1. Statistics
Statistical analysis was performed with IBM SPSS Statistics software (version 23). Continuous 
data (presented as the means ± SD) that were normally distributed were analysed using 
Student’s t-test, while data that were not normally distributed were analysed using the Mann–
Whitney U test. The Pearson’s exact chi-square or Fisher’s exact test were used to compare 
the proportions between groups. Progression-free survival was defined as the time interval 
between the end of primary treatment and the date of progression. If there was no docu-
mented recurrence, PFS was calculated from the end of primary treatment to the date of last 
follow-up or death. Platinum-resistant relapse was defined as recurrence within 6 months of 
primary treatment. Overall survival was defined as the time interval between date of diagno-
sis and date of death or last follow-up. Progression free survival and OS were analysed by the 
log-rank test and the results were expressed as Kaplan–Meier plots. A Cox proportional haz-
ards model was estimated to assess the impact of different prognostic variables on survival. A 
p value <0.05 was defined as statistically significant.
3. Results
3.1. Cases
Two hundred and fifty-seven patients were registered in the ROR-Sul database and 147 (58%) 
of those received systemic treatment and were included in this analysis. Excluded patients 
either were not submitted to surgery or chemotherapy in our centre, died without any spe-
cific treatment, had non-eligible neoplasia after surgery (3 mucinous adenocarcinomas of the 
appendix) or were diagnosed with early stage disease with low-risk features (Figure 1).
Demographic and clinical characteristics are summarised in Table 1. All 147 patients were 
treated with platin-based chemotherapy: either following primary surgery (n = 94, 64%) or 
in the neoadjuvant setting (n = 53, 36%). The mean age at diagnosis was 60.4 years (25–89; 
IC95% = [58.4–62.4]); patients in NACT group were older (64.3 vs. 58.2; p = 0.002) and we did 
not observe age differences between advanced versus non-advanced stages, different histo-
logic subtypes or between platinum-resistant versus platinum-sensitive patients (p = 0.318; 
p = 0.108; p = 0.774, respectively). More cases of advanced disease were treated with NACT 
(6% stages IIIB, 83% IIIC-IV) as compared with primary surgery (27% stages IA-IC, 36% IIA-
IIIB, 37% IIIC-IV). The median number of chemotherapy cycles was superior in the NACT 
group (8 vs. 6; p = 0.000). Macroscopic residual disease after debulking surgery (PDS or 
IDS) was present in 46% of all cases (IC95% = [37%; 54%]) and was not associated with the 
treatment modality (Pearson X2 = 0.001; p = 1.000). Most cases were serous, endometrioid or 
carcinomas not otherwise specified (NOS) (58.5, 14.3 and 15%, respectively); 9 patients (6%) 
had cancers with mucinous/clear cell histology. The proportion of serous carcinomas was 
similar between groups. In the PDS group, a significantly higher proportion of endometrioid 
tumours was observed (20 vs. 2%; p = 0.021) while carcinomas NOS were more frequent in the 
NACT group (16 vs. 6%; p = 0.021). Thirty-six patients (24.4%) had information of molecular 
testing: 23 in the PDS (7 BRCA carriers) and 13 in the NACT (4 BRCA carriers and 1 RAD51C 
carrier) groups.
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Figure 1. Study design. OC: Ovarian cancer; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; IDS: 
Interval debulking surgery.
PDS (N = 94) NACT–IDS (N = 53) P
Age (mean, years) 58 (±12) 64 (±10) 0.002
Histology [N(%)]
Serous 54 (57.4) 32 (60.4) 0.021
Endometrioid 19 (20.4) 2 (3.8)
Mucinous 3 (3.2) 1 (1.9)
Clear cell 4 (4.3) 1 (1.9)
Mixed 2 (2.1) 0 (0)
Poorly differentiated 6 (6.4) 1 (1.9)
Carcinoma NOS 6 (6.4) 16 (30.2)
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3.2. Treatment decision
The decision for NACT was due mainly to radiological criteria: implants >2 cm outside the pelvis 
(18 pts; 34%), lymphadenopathies above renal hilum (12 pts; 23%), subcapsular or Parenchymal 
liver metastasis (8; 15%) or pre-sacred retroperitoneal disease (1 pt; 2%). In 14 pts (26%), comor-
bidities that contraindicated upfront surgery were also considered in the decision for NACT.
3.3. Efficacy analysis
For the total cohort, the median PFS and OS were 13.4 (IC95%= [9,3-17,5]) and 44.0 
(IC95% = [29.7–58.3]) months, respectively. In the PDS group, PFS was significantly superior 
(23.4 vs. 13.8 months; p = 0.010), even when restricting analysis to advanced stages (21.4 vs. 12.5 
months; p = 0.040). Patients with no macroscopic residual disease after debulking surgery had 
superior PFS (27.0 vs. 14.0 months; p = 0.000).
For patients treated with PDS, OS was significantly superior (48.4 vs. 30.9 months; p = 0.001), 
even when restricting the analysis to advanced stages (44.4 vs. 28.2 months; p = 0.014) (Figure 2).
Patients with no macroscopic residual disease after debulking surgery had superior OS (52.7 
vs. 36.0 months; p = 0.002) (Figure 3), as well as those with non-advanced stage disease (52.5 
vs. 37.1 months; p = 0.009). Moreover, patients with platinum-sensitive relapse (>6 months) 
had significantly superior OS (56.0 vs. 12.3 months; p = 0.000) (Figure 4), as compared to plati-
num resistant patients.
The Cox proportional hazards model (Table 2) allowed estimating the impact in survival 
of factors such as age at diagnosis, histology, stage, platinum free interval, residual dis-
ease after debulking surgery and therapeutic modality. Adjusting for these variables, the 
PDS (N = 94) NACT–IDS (N = 53) P
FIGO Stage [N(%)]
IA-IC 25 (26.6) — 0.000
IIA-IIC 17 (18.1) —
IIIA 5 (5.3) —
IIIB 12 (12.8) 3 (5.7)
IIIC 21 (22.3) 15 (28.3)
IV 14 (14.9) 29 (54.7)
Unknown — 6 (11.3)
Nr of cycles (median) 6 (±1.3) 8 (±2.7) 0.000
Residual disease after debulking 
surgery [N(%)]
60 (64) 29 (55) 1.000
Table 1. Demographic and clinical characteristics of the study population. PDS: Primary debulking surgery; NACT-
IDS: Neoadjuvant chemotherapy and interval debulking surgery; NOS:  Not otherwise specified; Values for continuous 
measurements are means, unless otherwise specified; FIGO: International Federation of Gynecology and Obstetrics.
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only  statistically significant prognostic factor for both relapse and death was the presence 
of macroscopic residual disease after surgery, with more than 2-fold higher risk of relapse 
(HR = 2267; p = 0.000) and 80% higher risk of death (HR = 1847; p = 0.036). Primary debulking 
surgery was associated to a significantly better outcome, but only in terms of PFS (HR = 0.541; 
p = 0.012), with no significant gain in OS compared to NACT, although there is a trend to a 
better outcome (HR = 0.714; p = 0.296). Other factors, such as age, histology or advanced stage 
did not have a significant effect on relapse. Platinum-resistant disease was associated with a 
9-fold higher risk of death (HR = 8964; p = 0.000). There is a trend towards a worse prognosis 
of advanced stage disease (HR = 1293; p = 0.468) and towards a better outcome of serous his-
tology (HR = 0.847; p = 0.560).
Figure 2. Kaplan–Meier survival curves showing the PFS and OS rates of patients in the NACT/IDS vs. PDS groups (only 
advanced stages) (7.3 vs. 13.4 months; p = 0.010 and 21.0 vs. 55.1 months; p = 0.001, respectively).
Figure 3. Kaplan–Meier survival curves showing the PFS and OS rates of patients with vs. without macroscopic residual 
disease after debulking surgery (PFS: 9.9 vs. 25.1 months, p = 0.000; as it did not fall below 50% at the time of the analysis, 
it is not possible to estimate median OS, p = 0.002).
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OS PFS
Coefficient SE P HR (95% 
CI)
Coefficient SE P HR (95% CI)
Age 0.021 0.012 0.097 1021 
(0.996–1046)
0.004 0.008 0.559 1004 
(0.990–1020)
Serous histology 
(vs nonserous)
−0.166 0.285 0.560 0.847 
(0.484–1481)
0.323 0.194 0.096 1381 
(0.944–2020)
Advanced stage 
(stage III-IV vs. 
I-II)
0.257 0.354 0.468 1293 
(0.646–2590)
−0.315 0.243 0.195 0.730 
(0.453–1176)
Residual disease 0.603 0.293 0.036 1847 
(1040–3278)
0.818 0.219 0.000 2267 
(1504–3416)
PDS (vs NACT) −0.337 0.322 0.296 0.714 
(0.380–1344)
−0.615 0.244 0.012 0.541 
(0.335–0.873)
Platinum 
resistant disease
2193 0.300 0.000 8964 (4976–
16.147)
— — — —
Table 2. Multivariate Cox regression model. OS: overall survival; PFS: progression-free survival; SE: standard error; 
HR: hazard ratio; CI: confidence interval; PDS (vs NACT): primary debulking surgery (vs neoadjuvant chemotherapy).
Figure 4. Kaplan–Meier survival curves showing OS rates of patients with platinum-sensitive vs. platinum-resistant 
relapse after primary treatment (63.0 vs. 8.0 months, p = 0.000).
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Ninety seven percent (97%) of patients relapsed and almost 1/3 of these (46 pts) had platinum-
resistant disease (31%; IC95% = [23%; 39%]). The treatment strategy (NACT vs. PDS) and 
residual disease after debulking surgery were not associated with the occurrence of relapse 
(Pearson X2 = 2318 and p = 0.297; Pearson X2 = 0.708 and p = 0.625, respectively).
At the time of this analysis, all BRCA carriers (7/7) in the PDS and 75% of BRCA carriers in the 
NACT (3/4) group were alive as compared to 54 and 36% of patients with unknown BRCA 
status, respectively.
4. Discussion
Between 2006 and 2011, NACT was decided as primary approach for advanced OC, mostly 
for patients with radiologically determined unresectable disease and for older patients 
with comorbidities. Independently of the therapeutic modality, non-advanced stage at 
diagnosis and absence of residual disease after surgery were associated with progres-
sion free survival. Adjusting for age at diagnosis, histology, stage, platinum free inter-
val, residual disease after surgery and therapeutic modality (either NACT or PDS), the 
only statistically significant prognostic factor for both relapse and death was the presence 
of macroscopic residual disease after surgery. Primary debulking surgery was associated 
with a significantly better outcome only in terms of PFS, although a trend to a better OS 
was also observed. When analysis was restricted to stages III and IV OS was significantly 
superior in the PDS group, as compared with the NACT group. BRCA status was known 
for a small proportion of patients in both groups, which limits statistical analysis and con-
clusions. However, it’s interesting to note that all known BRCA carriers in the PDS group 
were alive at the time of this analysis, compared to only 75% after NACT-IDS. That hap-
pens for unknown BRCA status patients as well, but with a smaller difference between 
groups (54 vs. 36%). Recent observations suggest a selection of tumour cell clones without 
somatic loss of heterozygosity (LOH) for the wild-type allele of BRCA genes, during neo-
adjuvant therapy [39].
Patients treated with PDS had better outcome in terms of PFS. This is not unexpected since 
this group included patients with less advanced disease, but suggests that the cytotoxic treat-
ment before primary surgery in the NACT group could not counteract the bad prognosis asso-
ciated with advanced stage. This was observed even if patients in the NACT group received 
a higher number of chemotherapy cycles (8 vs. 6; p = 0.000). Some authors have expressed 
concern about the selection of resistant clones in patients submitted to NACT [34–36] but 
we did not observe an association between the platinum free interval and the chosen treat-
ment approach (Pearson X2 = 3955 and p = 0.058). Patients with platinum-sensitive relapse 
(>6 months) had significantly superior OS (56.0 vs. 12.3 months; p = 0.000), as compared to 
platinum resistant patients. This was confirmed in the multivariate survival analysis, with 
Cox model showing that platinum-resistant disease was associated with a 9-fold higher risk of 
death (HR = 8964; p = 0.000). These findings should be carefully interpreted, since further lines 
of treatment widely vary between platinum-sensitive and platinum-resistant populations. 
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There is evidence that longer platinum-chemotherapy-free interval is associated with better 
survival (especially PFS after further lines of treatment) [40], but although the platinum-free 
interval is defined as the period of time from the last date of platinum dose until progressive 
disease is documented, it does not take into account how progression is defined (CA125 alone, 
radiological and symptomatic recurrence) [41].
The PDS group had a significantly higher number of patients with endometrioid histology. 
This factor and more advanced cases in the NACT group, may have contributed to the better 
outcomes in patients submitted to upfront surgery. The higher proportion of carcinoma NOS 
in NACT group (16 vs. 6%; p = 0.021) is a limitation of our study, since consecutive pathology 
review was not done. However, this finding is not unexpected in pathology reports of surgical 
specimens after NACT.
We did not observe an improvement of optimal debulking rates with NACT, as macroscopic 
residual disease after debulking surgery (PDS or IDS) was not associated with the treat-
ment strategy (Pearson X2 = 0.001; p = 1.000). In the 2010 EORTC-NCIC trial, no gross resid-
ual tumour after PDS was achieved in 19% of patients and after IDS in 51% of patients [25]. 
Progression-free survival and OS for both arms were 12 and 30 months, respectively. In our 
cohort, cytoreduction was higher (36%) in the PDS group, as well as PFS and OS (13.4 and 
55.1 months, respectively). Cytoreduction rate for our NACT group (45%) was closer to the 
rate described in the EORTC trial but our observations for PFS and OS were lower (7.3 and 
21.0 months, respectively). Besides the expected differences between a randomised trial and 
an observational study, stage IV patients were well-balanced between arms in the EORTC trial 
but predominated in the NACT group (55 vs. 15%) of our study. In the CHORUS trial the com-
plete cytoreduction rate was inferior to the one in our cohort, both in PDS and NACT groups 
(15 vs. 35%) but PFS and OS outcomes with NACT were better (10 and 23 months, respec-
tively) than with PDS (12 and 25 months, respectively) [42]. However, a recent observational 
trial [32] showed NACT to be inferior to PDS in stage IIIC but superior in stage IV. It is impor-
tant to remember that, for this analysis, we considered complete cytoreduction as the absence 
of macroscopic residual disease, even if, this was not the case for other studies [25, 32, 42].
Although retrospective, our study reflects how decisional criteria for both modalities were 
applied in a group of consecutive, non-selected OC patients. Statistical methodologies were 
selected according to the retrospective nature of the study: univariate analysis first identified 
factors influencing the outcomes of these patients (other than primary treatment); these factors 
were then integrated in the multivariate analysis (Cox regression model), to ascertain the effi-
cacy of each strategy, adjusting to variables previously identified as an influence to prognosis. 
Limitations to this study are possible selection and recall bias, as well as unknown confounding 
variables that may have a negative impact on the accuracy of the results. One example is the lim-
ited accuracy in determining performance status and comorbidities as criteria for the decision of 
upfront treatment, although notes from multidisciplinary meetings were carefully reviewed. As 
for the assessment of residual disease after debulking surgery, heterogeneity was observed due to 
changing criteria for the classification of ideal resection during the period covered by our study.
In conclusion, the only significant prognostic factor for both relapse and death was the 
presence of macroscopic residual disease after surgery, which enhances the importance of 
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 maximal cytoreduction in the primary treatment. As for the influence of treatment modality 
on outcomes, PDS was associated to a significantly better PFS and a non-significant trend to 
a better OS. Other factors, such as age, histology or advanced stage did not have a significant 
effect on relapse. Our findings are in agreement with other studies [19, 20, 25, 32, 42, 43] 
about the impact of optimal debulking surgery in survival of OC patients. This is observed 
whether complete debulking is attained with easily resectable disease or extensive surgery. 
It has also been shown that the impact of potentially negative biologic factors such as grade 
and histology can be overcome by surgical debulking [43]. This is why surgical expertise plus 
supportive management (antibiotics, blood banking, and intensive care) should parallel the 
development of better systemic therapies.
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